RLYB News and Press, Rallybio Corporation From 11/28/23

2023-11-28 13:46:03 ET More on Rallybio Rallybio: Gearing Up To Be An Opportunity Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio For further details see: Rallybio posts earl...

-- Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study -- -- RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies in Pregnant Women -- -- RLYB212 Phase 2 Study Expected To Comme...

2023-11-09 12:28:05 ET More on Rallybio Rallybio: Gearing Up To Be An Opportunity Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio For further details see: Rallybio GAAP EPS o...

-- RLYB212 Phase 1 Multiple Dose Cohort Complete and on Track for 4Q 2023 Data Release -- -- Initial Data from RLYB116 Phase 1 Multiple Ascending Dose Study Including Safety, PK and PD on Track for 4Q 2023 Release -- -- $121.4 million cash, cash equivalents and marketable securiti...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Rallybio Corporation (RLYB) is expected to report $-0.51 for Q3 2023

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held...

2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will parti...

2023-09-15 17:15:40 ET Summary Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C...